| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| IgG3 Fc | Human IgG3 Fc Protein, Tag Free (MALS & SPR verified) |  Human | HEK293 |  | MALSSDS-PAGE | $280.00 200ug | ||
| IgG3 Fc | Avitag IG3-H8213 | Biotinylated Human IgG3 Fc Protein, Avitag™ (MALS verified) | Human | HEK293 |  | MALSSDS-PAGE | $360.00 25ug | |
| IgG3 Fc | Mouse IgG3 Fc Protein, Tag Free (MALS verified) |  Mouse | HEK293 |  | MALSSDS-PAGE | $325.00 200ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ricefidase | KJ-103; KJ103 | Phase 3 Clinical | Shanghai Bao Pharmaceuticals Co Ltd | Anti-Glomerular Basement Membrane Disease; Guillain-Barre Syndrome; Rejection of renal transplantation | Details |
| AT-02 | AT-02 | Phase 2 Clinical | Attralus Inc | Amyloidosis; Immunoglobulin Light-chain Amyloidosis | Details |
| JZB-34 | AAFP; JZB-34 | Phase 1 Clinical | Shanghai Kexin Biotech Co Ltd | Hypersensitivity | Details |
| Emicizumab biosimilar (Jushi Biopharmaceutical) | SYS6053; SYS-6053 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Hemophilia A; Hemorrhage | Details |
| S-1117 | S-1117 | Phase 1 Clinical | Seismic Therapeutics Inc | Immune System Diseases | Details |
| BHV-1300 | BHV-1300 | Phase 1 Clinical | Biohaven Pharmaceuticals Inc | Arthritis, Rheumatoid; Graves Disease | Details |
| HNSA-5487 | HNSA 5487; HNSA-5487 | Phase 1 Clinical | Hansa Biopharma Ab | Autoimmune Diseases; Neoplasms | Details |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Imlifidase | Mac-1 | Approved | Hansamed Inc | Idefirix | EU | Rejection of renal transplantation | Hansa Biopharma Ab | 2020-08-25 | Guillain-Barre Syndrome; Kidney Diseases; Kidney Failure, Chronic; Purpura, Thrombotic Thrombocytopenic; Rejection of renal transplantation; Rejection of organ transplantation; Renal Insufficiency, Chronic | Details |
